First patient dosed in ACCEL, a 700‑patient, 26‑week, randomized, double‑blind, placebo‑controlled Phase 3 trial assessing twice‑daily tenapanor (IBSRELA) in adults with chronic idiopathic constipation. The primary endpoint centers on patient‑reported constipation outcomes, with enrollment running through 2026 and topline data targeted for the second half of 2027.
The core move is straightforward: Ardelyx is pursuing a label expansion from IBS‑C to CIC for tenapanor, aiming to translate an established mechanism into a broader, high‑prevalence indication. The study design puts durability front and center, extending blinded treatment to six months rather than the more common 12‑week primary assessment seen in many CIC programs. If successful, the dataset could support a supplemental filing in the U.S., while also serving payers and guideline committees that increasingly emphasize longer‑term symptom control, adherence, and health‑related quality of life in chronic GI disorders.
Strategically, this is an expansion play that also functions as a hedge. IBSRELA has commercial traction in IBS‑C, but CIC is larger and more diffuse, with entrenched incumbents, step‑edit norms, and payer algorithms that favor drugs with broad evidence packages. A robust, long‑horizon Phase 3 signal could strengthen negotiations on coverage and positioning, and create operating leverage across the same GI prescriber base. The twice‑daily regimen and differentiated mechanism may appeal to subsets who cycle through secretagogues or 5‑HT4 agonists; however, tenapanor’s known GI tolerability profile, including higher rates of diarrhea seen in prior IBS‑C trials, will require careful management to maintain persistence over 26 weeks. That tradeoff—potentially faster onset via NHE3 inhibition versus tolerability—sits at the center of the program’s clinical and commercial calculus.
For sites and CROs, a 26‑week double‑blind window with patient‑reported endpoints increases operational complexity. Daily stool and symptom diaries are table stakes, putting eCOA compliance and data integrity under the microscope. Expect tight run‑in and washout controls, defined rescue‑medication rules, and proactive AE counseling to mitigate discontinuations tied to diarrhea and related GI events. Retention pressure will be high, particularly as competition for CIC patients spans community GI and primary care. Vendors positioned to support adherence monitoring, remote check‑ins, and rapid AE triage should see opportunity; decentralized elements could reduce visit burden, but the need for consistent, high‑fidelity PRO capture will limit how far sponsors can push virtual models without risking endpoint variability. Regulators will focus on durable responder rates and consistency across baseline severity strata, while payers will look for clinically meaningful improvements in function and productivity, not just stool frequency.
The open questions are largely about sufficiency and speed. One pivotal of this size and duration may or may not satisfy regulators for a new indication, depending on effect size, safety, and the totality of supportive evidence. If the signal is modest or discontinuations run high, Ardelyx could be forced into a second study, pushing timelines beyond current guidance. Conversely, a clear, durable benefit with manageable tolerability could accelerate an sNDA and sharpen the company’s negotiating position with formularies. Watch for clarity on the exact primary endpoint construct and responder definition, discontinuation and rescue‑medication rates at interim operational updates, and whether Ardelyx layers in additional health‑economics and work‑productivity measures to fortify payer narratives. The next 18 months will be defined less by scientific novelty than by execution: enrollment cadence, PRO compliance, and retention will determine whether this expansion bid lands with regulators and the market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
